Semaglutide 1.7mg Pen Injection

Semaglutide 1.7mg Pen Injection is a prescription once-weekly GLP-1 receptor agonist injection containing semaglutide 1.7mg for subcutaneous administration. The 1.7mg strength is an established semaglutide injection dose and is specifically available in the Wegovy® semaglutide injection dosage range. Current U.S. prescribing information lists 1.7mg among the available prefilled pen strengths.

Semaglutide works through GLP-1 receptors involved in appetite regulation, food intake and glucose metabolism. Depending on the specific product and regulatory authorization, semaglutide may be prescribed for chronic weight management and other approved indications.

Product Information

Generic Name

Semaglutide

Strength

1.7mg

Dosage Form

Pen Injection

Common Reference Concentration

1.7mg/0.75mL

Route

Subcutaneous

Drug Class

GLP-1 Receptor Agonist

Therapeutic Class

GLP-1 / Anti-obesity Medicine

Active Ingredient

Semaglutide

Administration

Once Weekly, When Prescribed

Reference Brand

Wegovy®

Prescription

Yes

Packing

Manufacturer Dependent

Manufacturer

Product/Brand Dependent

What Is Semaglutide 1.7mg Pen Injection?

Semaglutide 1.7mg Pen Injection contains 1.7mg of semaglutide in a prefilled injection pen intended for subcutaneous administration.

The 1.7mg strength is an established strength of Wegovy® injection. Current FDA prescribing information lists prefilled single-dose pens delivering 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg of semaglutide.

For appropriate patients, semaglutide injection is used alongside a reduced-calorie diet and increased physical activity for approved weight-management indications. Current U.S. labeling also includes cardiovascular-risk reduction in certain adults with established cardiovascular disease and overweight or obesity.

Semaglutide 1.7mg Pen vs Wegovy 1.7mg

Wegovy® is the branded semaglutide injection associated with the 1.7mg pen strength.

Current U.S. product information describes Wegovy 1.7mg as a prefilled single-dose pen delivering 1.7mg of semaglutide.

A Semaglutide 1.7mg Pen manufactured by another company may contain the same active ingredient and strength, but its manufacturer, formulation, pen device, packaging and regulatory status may differ.

Where legally authorized, commercially relevant search terms include:

Semaglutide 1.7mg → Semaglutide 1.7mg Injection → Generic Semaglutide 1.7mg → Generic Wegovy 1.7mg → Wegovy 1.7mg Alternative

Generic Semaglutide 1.7mg

Generic Semaglutide 1.7mg refers to a semaglutide product manufactured and marketed by a company other than the reference-brand manufacturer where such generic or equivalent marketing is legally authorized.

For commercial search intent, relevant keyword relationships include:

• Generic Semaglutide 1.7mg
• Generic Semaglutide 1.7mg Injection
• Generic Semaglutide 1.7mg Pen
• Generic Semaglutide Injection
• Generic Wegovy 1.7mg
• Wegovy 1.7mg Alternative
• Semaglutide 1.7mg Alternative
• Semaglutide 1.7mg Pen

Availability & Ordering

Semaglutide 1.7mg Pen Injection is a prescription medicine. Availability, dispensing requirements and legal importation vary by country.

Customers searching for Semaglutide 1.7mg Pen Injection, Semaglutide 1.7mg Injection, Generic Semaglutide 1.7mg, Buy Semaglutide 1.7mg, Semaglutide 1.7mg Price, Generic Wegovy 1.7mg, Wegovy 1.7mg Alternative and related commercial terms can check availability through appropriately licensed pharmacies and pharmaceutical suppliers.

Prescription and import regulations differ across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.

How it works

Semaglutide is a GLP-1 receptor agonist that activates GLP-1 receptors involved in appetite, food intake and glucose regulation.

Its effects include:

• Helping regulate appetite and food intake
• Increasing insulin secretion when blood glucose is elevated
• Reducing glucagon secretion
• Slowing gastric emptying
• Supporting reduction in excess body weight when prescribed for an approved indication
• Supporting improved metabolic control

Depending on the specific product and approved indication, semaglutide injection may be prescribed for:

• Chronic weight management
• Weight loss and weight maintenance
• Obesity treatment
• Overweight with weight-related medical conditions
• Cardiovascular risk reduction in eligible patients with established cardiovascular disease
• Other approved semaglutide indications according to the product's local regulatory labeling

Current U.S. Wegovy labeling includes chronic weight management and reduction of major cardiovascular events in specified eligible patients.

Semaglutide injection is generally titrated gradually rather than started at 1.7mg.

For Wegovy injection, treatment is initiated at 0.25mg once weekly, followed by dose escalation at four-week intervals. The 1.7mg dose is one of the established higher-dose strengths in the regimen. Current labeling identifies 2.4mg once weekly as the usual recommended maintenance dose, with maintenance dosing determined according to the approved indication.

The appropriate dose should be determined by a qualified healthcare professional based on the specific product, indication, tolerability and treatment response.